A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors

Not yet recruitingOBSERVATIONAL

Enrollment

500

Participants

Timeline

Start Date

March 26, 2024

Primary Completion Date

November 26, 2027

Study Completion Date

May 26, 2028

Conditions

Neuroendocrine Tumors

Interventions

DRUG

Octreotide microspheres

20mg/30mg Q4W

Trial Locations (1)

Qilu hospital of Shandong University, Jinan

All Listed Sponsors

lead

Qilu Hospital of Shandong University

OTHER

NCT06300216 - A Real-world Study of Octreotide Microspheres in Chinese Patients With Neuroendocrine Tumors | Biotech Hunter | Biotech Hunter